Inventaire - your friends and communities are your best library

Ticagrelor in patients with diabetes and previous PCI

লেখক

Negar Manavifar

এতে প্রকাশিত: The Lancet

তারিখে প্রকাশিত: 2019-09-01

Cites articles 7

তারিখ

শিরোনাম

লেখকগণ

2019-09-01

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Jan H Cornel, Leonardo De Luca, Marcin Basiak, Darren K McGuire
2019-02-01

Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting

Gregg W Stone, Stephan Windecker, Ewout W. Steyerberg
2017-08-26

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Erkin Mirrakhimov, Tuomas Kiviniemi, Frans Van de Werf, Raffaele Bugiardini, Marco Valgimigli, Gregory Lip, Toomas Marandi, Gilles Montalescot, Patrizio Lancellotti, Robert A Byrne, Ulf Landmesser, Adnan Kastrati, Peter Jüni, Stephan Windecker, Elliott M Antman, Philippe Gabriel Steg, Piotr Ponikowski, Lina Badimon, Gerhard Hindricks, Michał Tendera, Udo Sechtem, Jean-Pierre Bassand, Freek Verheugt, Philippe Kolh, Laura Mauri, Pascal Vranckx, Hugo A. Katus, Andrzej Budaj, Franz-Josef Neumann, Anders Jeppsson, Felicita Andreotti, Christian W Hamm, Robert F. Storey, Eugène P McFadden, Luc Pierard, Maddalena Lettino, Mate Petricevic, Miguel Sousa Uva, Mustafa Cikirikcioglu, Thomas Cuisset, Victora Delgado, Nazzareno Galié, Stefan James, Markus Schwerzmann, Patrizio Lancellotti, Christoph Varenhorst, Walter J Desmet, Robert Gabor Kiss, Borja Ibanez, Jurrien ten Berg, Erik Lerkevang Grove, Sasko Kedev, Franz Xaver Roithinger, Marco Zavatta, Steffen Massberg, Eli I Lev, Zlatko Fras, Jean-Philippe Collet
2017-03-01

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.

Philippe Gabriel Steg, Marco Valgimigli, Myeong-Ki Hong, Lars Wallentin, Stephan Windecker, Lorenz Räber, Gregg W Stone, Ewout W. Steyerberg, Thomas Pilgrim, David van Klaveren, Dik Heg, Stefan James, Deepak L. Bhatt, Thomas Zanchin, Fausto Feres, Tullio Palmerini
2015-04-16

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

Francesco Costa, Gianfranco Parati, Malte Kelm, Marco Valgimigli, Gregory Lip, Michalina Kolodziejczak, Felicita Andreotti, Eliano Pio Navarese, Marc Brouwer, Mariusz Kowalewski
2009-06-15

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study

Marco Valgimigli, Gianluca Campo, Pascal Vranckx
2006-04-20

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Gilles Montalescot, Eric Topol, Patrice Cacoub, Graeme J. Hankey, Steven R Steinhubl, Deepak L. Bhatt, Peter B. Berger, Danielle M Brennan, Clay Johnston, Eric A Cohen

নিবন্ধ - wd:Q93104341

জায়ে আপনাকে স্বাগত

the library of your friends and communities

আরো জানুন